Back

The Landscape of Prostate Tumour Methylation

Arbet, J.; Shiah, Y.-J.; Yamaguchi, T. N.; Hugh-White, R.; Wiggins, A.; Oh, J.; Gebo, T.; Foucal, A.; Lesurf, R.; Jung, C.-H.; Dang, R. M. A.; Agrawal, R.; Livingstone, J.; Salcedo, A.; Yao, C. Q.; Espiritu, S. M. G.; Houlahan, K. E.; Yousif, F.; Heisler, L. E.; Fraser, M.; Kishan, A.; Berlin, A.; Chua, M. L.; van der Kwast, T.; Hovens, C. M.; Bristow, R. G.; Boutros, P. C.

2025-02-10 cancer biology
10.1101/2025.02.07.637178 bioRxiv
Show abstract

Prostate cancer is characterized by profound clinical and molecular heterogeneity. While its genomic heterogeneity is well-characterized, its epigenomic heterogeneity remains less understood. We therefore created a compendium of 3,001 multi-ancestry prostate methylomes spanning normal tissue through localized disease of all grades to poly-metastatic disease. A subset of 884 samples had multi-omic DNA and/or RNA characterization. We identify four epigenomic subtypes that risk-stratify patients and reflect distinct evolutionary trajectories. We demonstrate extensive regulatory interplay between DNA ploidy and DNA methylation, with transcriptional consequences that vary across genes and disease stages. We define the epigenetic dysregulation signatures of the 15 most important clinico-molecular features, creating predictive models for each. For example, we identify specific epigenetic features that predict patient outcome and that are synergistic with clinico-genomic prognostic features. These results define a complex interplay between tumour genetics and epigenetics that converges to modify gene-expression programs and clinical presentation.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.